EP-1958: Treatment results of Mammosite catheter in combination with whole breastirradiation

Gitt, A.; Böse-Ribeiro, Hugo; Nieder, Carsten; Kup, Philipp Günther; Hermani, Horst; Bühler, Hans; Ergönenç, H.Y.; Drüppel, D.; Adamietz, I. A.; Fakhrian, Khashayar

doi:10.1016/s0167-8140(16)33209-1

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a short follow-up period of 21 months, no ipsilateral breast-tumor recurrences have been observed with an acceptable toxicity profile of 28% asymptomatic and 10% symptomatic seroma in 90 days after treatment [97]. Another retrospective long-term single institute (N:157) results confirmed that rate of ipsilateral breast recurrence was low as 2.5% at a median followup time of 5.5 years (range 0-10.0 years).…”

Section: Accelerated Partial Breast Radiotherapymentioning

confidence: 75%

Modern Radiotherapy Era in Breast Cancer

Bölükbaşı¹,

Selek²

2017

Breast Cancer - From Biology to Medicine

View full text Add to dashboard Cite

Radiation therapy (RT) is one of the major treatment modalities that are used in breast cancer treatment, and depending on the chest-wall anatomy, RT fields have to be customized. Techniques used in planning have been evolving since last two decades from two dimensional (2D) to three-dimensional (3D), while intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and even proton therapy have been an option in daily approach. In addition, technological hardware and software advances in delivery and planning systems, total treatment duration of breast RT have been shortened in last decades along with recent hypofractionated radiotherapy schemes or emerging partial-breast irradiation protocols. The other attractive approach-accelerated partial breast irradiation (APBI) could be a reasonable option for highly selected subpopulation of early-stage breast cancer patients out of a clinical trial. Long-term follow-up results have emerged heart and coronary sparing with maximum safety and efficacy. The most important advance could be named as cardiac sparing-deep breathhold approach-in all the modern technique improvement. Although most advanced techniques in management of breast cancer have not been verified to increase survival, we suggest recommending resource stratified advanced in order to provide best technical and clinical care in this long-term survivor candidates.

show abstract

Section: Accelerated Partial Breast Radiotherapymentioning

confidence: 75%

Modern Radiotherapy Era in Breast Cancer

Bölükbaşı¹,

Selek²

2017

Breast Cancer - From Biology to Medicine

View full text Add to dashboard Cite

show abstract

“…After decades of breast cancer therapy improvements, locoregional adjuvant radiotherapy is regarded a safe and effective treatment (1)(2)(3)10). Nevertheless, typical and expected side-effects are often observed, e.g.…”

Section: Discussionmentioning

confidence: 99%

Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort

et al. 2022

View full text Add to dashboard Cite

“…Whole breast radiotherapy using external beam with a prescription dose of 50 Gy in 25 treatments leads to skin toxicity rates of 31%-49%, though the rates are lower using hypofractionation (Lilla et al 2007, Pignol et al 2008. Brachytherapy APBI is well tolerated, with acute toxicity rates, including moist desquamation, ranging from 7% to 39% (Pignol et al 2015, Gitt et al 2016, Ott et al 2016. Moist desquamation is correlated to long term skin toxicity including telangiectasia, which impacts on cosmesis (Lilla et al 2007, Pignol et al 2016 and eventually impacts on the health related quality of life (Pignol et al 2016).…”

Section: Introductionmentioning

confidence: 99%

Radiochromic film in vivo dosimetry predicts early the risk of acute skin toxicity for brachytherapy partial breast irradiation

et al. 2020

View full text Add to dashboard Cite

Brachytherapy accelerated partial breast irradiation (APBI) is well tolerated, but reported acute toxicities including moist desquamation rates range from 7% to 39%. Moist desquamation is correlated to long-term skin toxicity and high skin dose is the main risk factor. This study uses radiochromic films for in vivo skin dosimetry of low dose rate (LDR) APBI brachytherapy and prediction of skin toxicity. Patients participating in a clinical trial assessing skin toxicity of LDR seed brachytherapy were included in this study. Following the seed implantation procedure, patients were asked to wear a customized oval shaped radiochromic film on the skin projection of the planned target volume (PTV) for 24 h. Exposed films were collected, and maximum point doses were measured. In addition, maximum doses to a small skin volume (D0.2cc) were calculated on the pre- and post-implant CT-scan. Acute skin toxicities (redness, pigmentation, induration and dermatitis) were scored by the treating physician for 2 months during follow-up visits. Skin dose measurements and acute toxicity were available for 18 consecutive patients. The post-implant calculated maximum skin doses (D0.2cc), 60.8 Gy (SD ± 41.0), were on average 30% higher than those measured in vivo (Dmax-film), 46.6 Gy (SD ± 19.3), but those values were highly significantly correlated (Spearman’s rho 0.827, p < 0.001). Also, dermatitis and induration were significantly correlated with higher in vivo measured and post-implant calculated skin dose. Pre-implant dosimetry was not correlated with measured or post-implant skin dose or side effects. Radiochromic films can reliably diagnose excess dose to the skin during the first 24 h and predict skin toxicity, which enables preventative measures. Trial registration: Nederlands Trial Register (www.trialregister.nl), NTR6549, the trial was registered prospectively on 27 June 2017. ABR number: NL56210.078.16

show abstract

EP-1958: Treatment results of Mammosite catheter in combination with whole breastirradiation

Cited by 4 publications

References 0 publications

Modern Radiotherapy Era in Breast Cancer

Modern Radiotherapy Era in Breast Cancer

Implementation of Locoregional Adjuvant Radiotherapy for Breast Cancer in a Rural Healthcare Region: Toxicity Outcomes in the Initial Cohort

Radiochromic film in vivo dosimetry predicts early the risk of acute skin toxicity for brachytherapy partial breast irradiation

Contact Info

Product

Resources

About